{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:36:44Z","timestamp":1792431404622,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":122,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40265-020-01389-7","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T06:02:34Z","timestamp":1598680954000},"page":"1373-1378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Decitabine\/Cedazuridine: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,1]]},"reference":[{"issue":"4","key":"1389_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00277-020-03963-1","volume":"99","author":"JP Bewersdorf","year":"2020","unstructured":"Bewersdorf JP, Zeidan AM. Evolving therapies for lower-risk myelodysplastic syndromes. Ann Hematol. 2020;99(4):677\u201392.","journal-title":"Ann Hematol"},{"key":"1389_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719847059","author":"A Gil-Perez","year":"2019","unstructured":"Gil-Perez A, Montalban-Bravo G. Management of myelodysplastic syndromes after failure of response to hypomethylating agents. Ther Adv Hematol. 2019. https:\/\/doi.org\/10.1177\/2040620719847059.","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"1389_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1182\/blood-2018-03-785915","volume":"133","author":"V Santini","year":"2019","unstructured":"Santini V. How I treat MDS after hypomethylating agent failure. Blood. 2019;133(6):521\u20139.","journal-title":"Blood"},{"issue":"12","key":"1389_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11864-018-0581-6","volume":"19","author":"AM Hunter","year":"2018","unstructured":"Hunter AM, Zhang L, Padron E. Current management and recent advances in the treatment of chronic myelomonocytic leukemia. Curr Treat Options Oncol. 2018;19(12):67.","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"1389_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11523-020-00709-x","volume":"15","author":"HE Ramsey","year":"2020","unstructured":"Ramsey HE, Oganesian A, Gorska AE, et al. Oral azacitidine and cedazuridine approximate parenteral azacitidine efficacy in murine model. Targeted Oncol. 2020;15(2):231\u201340.","journal-title":"Targeted Oncol"},{"issue":"1","key":"1389_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13148-019-0709-y","volume":"11","author":"N Hattori","year":"2019","unstructured":"Hattori N, Sako M, Kimura K, et al. Novel prodrugs of decitabine with greater metabolic stability and less toxicity. Clin Epigenet. 2019;11(1):111.","journal-title":"Clin Epigenet"},{"issue":"4","key":"1389_CR7","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/S2352-3026(19)30030-4","volume":"6","author":"MR Savona","year":"2019","unstructured":"Savona MR, Odenike O, Amrein PC, et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019;6(4):e194\u2013e203.","journal-title":"Lancet Haematol"},{"key":"1389_CR8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004143","author":"G Garcia-Manero","year":"2020","unstructured":"Garcia-Manero G, Griffiths EA, Steensma DP, et al. Oral cedazuridine\/decitabine: a phase 2, pharmacokinetic\/pharmacodynamic, randomized, crossover study in MDS and CMML. Blood. 2020. https:\/\/doi.org\/10.1182\/blood.2019004143.","journal-title":"Blood"},{"key":"1389_CR9","unstructured":"US Food & Drug Administration. FDA approves oral combination of decitabine and cedazuridine for myelodysplastic syndromes [media release]. 7 Jul 2020. https:\/\/www.fda.gov\/."},{"key":"1389_CR10","unstructured":"Astex Pharmaceuticals. Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and Health Canada approval of INQOVI\u00ae (decitabine and cedazuridine) tablets [media release]. 7 Jul 2020. https:\/\/astx.com\/."},{"key":"1389_CR11","unstructured":"US Food & Drug Administration. Inqovi (decitabine and cedazuridine): US prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212576s000lbl.pdf. Accessed 25 Jul 2020."},{"key":"1389_CR12","unstructured":"Eisai Co Ltd. US subsidiary Eisai Inc. assigns worldwide rights for DNA methylation inhibitor Dacogen\u00ae to Otsuka [media release]. 31 Mar 2014. https:\/\/eisai.mediaroom.com\/."},{"key":"1389_CR13","unstructured":"Otsuka Pharmaceutical. Otsuka acquires rights to hematological cancer treatment Dacogen\u00ae from Eisai (US) [media release]. 31 Mar 2014. https:\/\/www.otsuka.co.jp\/en\/company\/newsreleases\/2014\/20140331_1.html."},{"key":"1389_CR14","unstructured":"Taiho Pharmaceutical, Otsuka Pharmaceutical. Otsuka and Taiho announce that Taiho will commercialize two of Astex Pharmaceuticals' drug candidates in North America [media release]. 10 Jun 2019. https:\/\/www.otsuka.co.jp\/en\/company\/newsreleases\/2019\/20190607_2.html."},{"issue":"Suppl 1","key":"1389_CR15","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2019-122980","volume":"134","author":"G Garcia-Manero","year":"2019","unstructured":"Garcia-Manero G, McCloskey J, Griffiths EA, et al. Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3 study (ASCERTAIN study) of an oral hypomethylating agent ASTX727 (cedazuridine\/decitabine) compared to IV decitabine [abstract no. 846]. Blood. 2019;134(Suppl 1):846.","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1007\/s40265-020-01453-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T00:00:00Z","timestamp":1609113600000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01389-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-020-01389-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01389-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T07:20:19Z","timestamp":1611818419000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-020-01389-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":15,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1389"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01389-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"1 January 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Decitabine\/Cedazuridine: First Approval, written by Sohita Dhillon, was originally published electronically in SpringerLink on 29 August 2020 without open access.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate and consent for publication, Availability of data and material, Code availability"}}]}}